Latest Pharma Insights
Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026
Reddy’s Brazil Setback Signals Tougher Semaglutide Path
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026
Pipeline Watch: Seven Approvals And A Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 20, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 20, 2026
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial
With MIRANDA joining earlier Phase III wins, AstraZeneca is building a consistent evidence base for tozorakimab that analysts say could expand biologic use beyond currently targeted COPD populations.
Scrip - April 20, 2026
With MIRANDA joining earlier Phase III wins, AstraZeneca is building a consistent evidence base for tozorakimab that analysts say could expand biologic use beyond currently targeted COPD populations.
Scrip - April 20, 2026
Medtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026
The Chemist Who Wants To Reprogram Drug Discovery
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026
Alphamab Pursues Differentiated Approach To Next-Gen ADCs
In the space of antibody-drug conjugate, Alphamab Oncology’s CEO talks to Scrip about views on future partnership strategies and differentiation approaches for developing next-generation molecules.
Scrip - April 20, 2026
In the space of antibody-drug conjugate, Alphamab Oncology’s CEO talks to Scrip about views on future partnership strategies and differentiation approaches for developing next-generation molecules.
Scrip - April 20, 2026
Pipeline Watch: Seven Approvals And A Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 20, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 20, 2026
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial
With MIRANDA joining earlier Phase III wins, AstraZeneca is building a consistent evidence base for tozorakimab that analysts say could expand biologic use beyond currently targeted COPD populations.
Scrip - April 20, 2026
With MIRANDA joining earlier Phase III wins, AstraZeneca is building a consistent evidence base for tozorakimab that analysts say could expand biologic use beyond currently targeted COPD populations.
Scrip - April 20, 2026
Alphamab Pursues Differentiated Approach To Next-Gen ADCs
In the space of antibody-drug conjugate, Alphamab Oncology’s CEO talks to Scrip about views on future partnership strategies and differentiation approaches for developing next-generation molecules.
Scrip - April 20, 2026
In the space of antibody-drug conjugate, Alphamab Oncology’s CEO talks to Scrip about views on future partnership strategies and differentiation approaches for developing next-generation molecules.
Scrip - April 20, 2026
Medtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026
CRN Urges White House To Leave Dietary Ingredients Uncovered By Blanket Tariffs Order
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
If dietary ingredients “inadvertently captured in tariff actions stemming” from administration’s Section 301 investigations, “there could be severe ramifications to the US manufacturing operations of the dietary supplement industry,” CRN says in comments.
HBW Insight - April 19, 2026
Reddy’s Brazil Setback Signals Tougher Semaglutide Path
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026
Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026
The Chemist Who Wants To Reprogram Drug Discovery
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026